Dendreon's Provenge received earlier than expected approval by the European Medical Agency. It will now be possible to sell the prostate cancer therapy in Europe. It is likely to be a slow ramp, however, because each nation has to approve Provenge for reimbursement (they all have national health insurance in Europe) and a facility to process the Provenge (which involves tagging patient blood to make it attack the cancer) has to be built. Since two facilities are operating in the United States, at least they should know how to set up one more efficiently this time around. See Dendreon Provenge Approved in Europe press release.
I added to my Dendreon stock position, but note that with an exist market capitalization of half a billion, and little likelihood of reaching profitability even in 2014, this is still a very risky investment, not for the faint of heart. Don't bet money on Dendreon if you can't afford to lose it.
Followers know I have been reviewing the biotechnology stocks in the Nasdaq 100 at Seeking Alpha. The overview and comparison article on those stocks has been published:
Biotechs in the Nasdaq 100 Recap
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment